The American Society of Clinical Oncology issued new practice guidelines urging providers to discuss chemopreventive drugs with female patients at high risk of breast cancer. Providers should explain the risks and benefits of tamoxifen among high-risk women before menopause, and tamoxifen, raloxifene and exemestane after menopause. The recommendations were published in the Journal of Clinical Oncology.

Full Story:
HealthDay News

Related Summaries